NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

I mean, he's also on an ongoing medication for this rare mutation that was identified (maybe an NTRK fusion or similar predicting tissue-agnostic benefit, but very rare in cancers)

This is wonderful news for him, and DCVax may have worked for him, but this is textbook survivorship bias. Highly likely he's one of the "lucky ones" given the fact that he survived at all.

The fact that he lived from summer 2019 to early 2022 when he received the vaccine means he was already a "long-term" survivor when he finally got DCVax compared with the median OS of the SOC in the phase 3 trial.

Glad he has achieved benefit. Very curious to know what other medication he is receiving.